Medicon Valley Biomedical Newsletter

7TM Pharma A/S has announced positive results from its clinical Phase I/II study with its lead compound TM30338, a dual Y2-Y4 receptor agonist developed for the treatment of obesity and related disea...

7TM Pharma A/S announces the closing of a EUR 19 million Series C financing round. The round was led by LD Pensions in collaboration with Scottish Widows Investment Partnership and includes a signific...

The candidate drugs within the laquinimod, 57-57 and TASQ projects all belong to a chemical group called quinolines. The exact mode of action for quinoline compounds has so far not been defined. ...

ALK-Abelló A/S's tablet-based immunotherapy, GRAZAX, has been approved by the Swedish Medical Products Agency for the treatment of grass pollen allergy. ALK-Abelló will now submit further applications...

BioGaia has entered into an agreement with the Swiss pharmaceutical company, Ferring Pharmaceuticals. The agreement gives Ferring exclusive rights to sell BioGaia's Reuteri drops in Spain, Portuga...

BioInvent International AB and US-based Immusol, Inc. have announced a collaboration for the development of a fully human n-CoDeR antibody for the treatment of age related macular degeneration, AMD, a...

Coloplast A/S has signed an offer to acquire US-based Mentor Corporation' urology business for EUR 382.5 million. The acquisition of Mentor will strengthen Coloplast's position in Europe and t...

Covalent Group, Inc. has announced that it has entered into a definitive combination agreement with Remedium Oy, a privately held, full-service CRO based in Finland with offices in 8 countries through...

Dako A/S launches Eridan - a new generation of fully integrated systems to obtain high-quality test results and shorten response times from tissue sample to diagnosis. Eridan builds on...

Egalet A/S has announced the closing of a EUR 23.5 million financing in a private placement led jointly by new investors Atlas Venture and Index Ventures. Current investors, Bio Fund Finland, Dansk Ka...

Lundbeck has initiated phase I clinical trials with its pharmaceutical candidate Lu AA34893 to investigate the tolerability and pharmacokinetic profile of the compound in humans. Lu AA348...

Novo Nordisk A/S and the French biopharmaceutical company Innate Pharma SA have announced a major partnership to develop new drugs targeting natural killer, NK, cells. As part of the agreement, Novo N...

Novo Nordisk A/S and US-based Argos Therapeutics have entered into an agreement under which Argos has licensed to Novo Nordisk antibody technology for research and development of a treatment for syste...

Novo Nordisk has inaugurated a major expansion of its production facilities in Tianjin, China. The Tianjin plant has been designated Novo Nordisk's primary production base in the Asia Pacific region a...

Santaris Pharma A/S has announced that it has completed a EUR 40m private investment round. The investment in Santaris Pharma has been made by an international syndicate of premier life science ventur...

TopoTarget A/S and US-based CuraGen Corp. announce the initiation of patient dosing in a new Phase I trial with their small molecule histone deacetylase, HDAC, inhibitor, PXD101. The trial is the firs...

TopoTarget A/S and US-based CuraGen Corp. have initiated patient treatment in a new Phase Ib/II trial to evaluate their promising HDAC-inhibitor, PXD101 in combination with Velcade for the treatment o...